Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 103-109

  Liu, Ping ^a   Allaudeen, Hameed ^a   Chandra, Richa ^a   Phillips, Kem ^b   Jungnik, Arvid ^c   Breen, Jeanne D ^a   Sharma, Amarnath ^a  

^a PFIZER INC   (United States)

^b Sourland Biostatistics   (United States)

^c PHAROS GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MONONUCLEAR CELL; NEUTROPHIL; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; SYNCOPE; TASTE AVERSION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MALE; NEUTROPHILS; SERUM;

EID: 33846020066     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00852-06     Document Type: Article

References (21)

1. Amsden, G. W. 1996. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin. Ther. 18:55-72.
2. Amsden, G. W., and C. L. Gray. 2001. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J. Antimicrob. Chemother. 47:61-66.
3. Amsden, G. W., A. N. Nafziger, and G. Foulds. 1999. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob. Agents Chemother. 43:163-165.
4. Beal, S. L., and L. B. Sheiner. 1988-1998. NONMEM users guides, parts I-VIII. NONMEM Project Group C255. University of California at San Francisco, San Francisco.
5. Chandra, R., P. Liu, J. D. Breen, J. Fisher, C. Xie, R. LaBadie, R. J. Benner, L. J. Benincosa, and A. Sharma. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended release microsphere formulation of azithromycin. Clin. Pharmacokinet., in press.
6. Drehobl, M. A., M. C. De Salvo, D. E. Lewis, and J. D. Breen. 2005. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128:2230-2237.
7. Drusano, G. L., and W. A. Craig. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 9(Suppl. 3):38-44.
8. File, T. M., Jr. 2004. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin. Infect. Dis. 39(Suppl. 3):S159-S164.
9. Foulds, G., and R. B. Johnson. 1993. Selection of dose regimens of azithromycin. J. Antimicrob. Chemother. 31(Suppl. E):39-50.
10. Girard, D., J. M. Bergeron, W. B. Milisen, and J. A. Retsema. 1993. Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. J. Antimicrob. Chemother. 31(Suppl. E):17-28.
11. Girard, D., S. M. Finegan, M. W. Dunne, and M. E. Lame. 2005. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J. Antimicrob. Chemother. 56:365-371.
12. Gladue, R. P., G. M. Bright, R. E. Isaacson, and M. F. Newborg. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 33:277-282.
13. Gladue, R. P., and M. E. Snider. 1990. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34: 1056-1060.
14. Guillemot, D., C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-Kervroedan, G. Bouvenot, and E. Eschwege. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279:365-370.
15. Kupper, L., and K. Hafner. 1989. How appropriate are popular sample size formulas? Am. Statistician 43:101-105.
16. Nibbering, P. H., T. P. Zomerdijk, A. J. Corsel-Van Tilburg, and R. Van Furth. 1990. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J. Immunol. Methods 129:143-145.
17. Periti, P., T. Mazzei, E. Mini, and A. Novelli. 1993. Adverse effects of macrolide antibacterials. Drug Saf. 9:346-364.
18. Segreti, J., H. R. House, and R. E. Siegel. 2005. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med. 118(Suppl. 7A):21S-28S.
19. Takeshita, E., B. Matsuura, M. Dong, L. J. Miller, H. Matsui, and M. Onji. 2006. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J. Gastroenterol. 41:223-230.
20. Weber, F. H., Jr., R. D. Richards, and R. W. McCallum. 1993. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am. J. Gastroenterol. 88:485-490.
21. Wildfeuer, A., H. Laufen, and T. Zimmermann. 1996. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob. Agents Chemother. 40:75-79.